Along these lines, inhibition of 5‐LOX interferes with PGE2 release in vitro, suggesting that interfering with the LOX pathway may represent a new therapeutic tool in cancer also to re‐establish antitumor immunity [211]. This evidence concerns the gene LOX and cancer.